Hua Lu

Hua Lu

Auto-generated profile, based on publicly available information

Hua Lu

Transfusion Medicine Department, the Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2014 in Transfusion
Verified
Journal Article
Closed access
PDF file
HLHua Lu
Hua Lu
TJTianlun Jiang
Tianlun Jiang
RLRuqing Li
Ruqing Li
SWShichun Wang
Shichun Wang
QZQiang Zhang
Qiang Zhang
SZShuming Zhao
Shuming Zhao

11 January 2018 in Indian Journal of Hematology and Blood Transfusion
Verified
Journal Article
Closed access
PDF file
MSMin Song
Min Song
SZShuming Zhao
Shuming Zhao
TJTianlun Jiang
Tianlun Jiang
HLHua Lu
Hua Lu

15 July 2022 in Gastroenterology Research and Practice
Verified
Journal Article
Open access
PDF file
TXTing Xu
Ting Xu
YTYin Tian
Yin Tian
YWYi Wang
Yi Wang
ZYZhongmei Yi
Zhongmei Yi
CLChenchen Li
Chenchen Li
HLHua Lu
Hua Lu
Purpose. Peptic ulcer is a multifactorial and complex disease and affects a wide range of people worldwide. We provided a novel therapeutic approach for peptic ulcer and observed its effect. Methods. Peptic ulcer patients were enrolled from 2016 to 2017 in Chongqing and randomly assigned to two groups: a control group that used only rabeprazole and a platelet-rich plasma (PRP) group that received a combination therapy of autologous PRP (aPRP) and rabeprazole. The therapeutic effect was assessed via the ulcer size and symptom score. Results. A total of 27 patients were included (12 patients in the control group and 15 patients in the PRP group) in this study. Our results showed that all participants have healed in 30 days, and there was no significant difference in healing time between the PRP group and the control group in different independent variables. However, regression analysis revealed that the healing time was 6.99 days shorter in the PRP group than that in the control group, and patients with higher symptom scores in the initial examination need more time to heal during treatment. Endoscopic results showed that the repaired ulcer in the PRP group was more similar to the normal gastric mucosa tissue than that the control group. Conclusion. This study showed an encouraging preliminary result that aPRP has a positive result in patients with peptic ulcer and seems to be a better choice for refractory peptic ulcer treatment. Although further follow-up studies are needed to determine the duration of efficacy of aPRP, the approach will be helpful in improving the clinical treatment of peptic ulcer.

1 April 2009 in Leukemia Research
Verified
Journal Article
Closed access
JLJian-Yong Li
Jian-Yong Li
LWLi-Xia Wang
Li-Xia Wang
WSWen-Yi Shen
Wen-Yi Shen
SLShi-Feng Lu
Shi-Feng Lu
LCLijuan Chen
Lijuan Chen
HLHua Lu
Hua Lu

30 June 2026 in Blood&Genomics
Verified
Journal Article
Open access
PDF file
HLHua Lu
Hua Lu
YZYi Zhu
Yi Zhu
QGQi Gao
Qi Gao
LZLuochuan Zhang
Luochuan Zhang
CWChao Wan
Chao Wan
FLFeng Liu
Feng Liu
This study aims to investigate the impact of blood type, antibody titer, and pregnancy history on the incidence and severity of ABO hemolytic disease of the newborn (HDN). Data from 214 ABO HDN cases (2018–2021) were analyzed using elution tests for diagnosis and transcutaneous bilirubin for severity. The positivity rate was significantly higher in the OA group (86.73%) than in the OB group (53.47%, P < 0.01), although differences in bilirubin levels between the two groups were limited. An antibody titer of ≥ 64 was associated with a marked increase in HDN incidence; however no consistent correlation with bilirubin levels was observed. Pregnancy history showed no significant correlation. Logistic regression identified blood type and antibody titer as significant predictors of HDN incidence (odds ration [OR] = 6.09, P < 0.01; OR = 1.001, P < 0.05), whereas pregnancy history was not statistically significant (OR = 0.633, P > 0.05). The prediction model, expressed as logit(P) = ln[P/(1−P)] = 0.023 + 1.806 × blood type (1) + 0.001 × titer − 0.457 × pregnancy history (1), achieved an area under the curve (AUC) of 0.776, indicating moderate predictive accuracy. The study suggests that newborn blood type and maternal antibody titer are key factors for predicting ABO HDN incidence, though not its severity, while pregnancy history has limited relevance. This predictive model provides a moderately accurate tool for risk assessment.

19 December 2022 in Vox Sanguinis
Verified
Journal Article
Closed access
GXGui‐Ping Xu
Gui‐Ping Xu
LWLi‐Fang Wu
Li‐Fang Wu
XXXiao‐Min Xu
Xiao‐Min Xu
JLJing‐Jing Li
Jing‐Jing Li
QGQi Gao
Qi Gao
HLHua Lu
Hua Lu